Peak ATP (Adenosine 5'-Triphosphate)
Also known as: ATP, Adenosine 5'-Triphosphate
Randomised trials show an acute single 400 mg dose improved total work in lower‑body resistance exercise in one small trial, while 14 days of lower doses (150–225 mg/day) produced limited, inconsistent strength benefits. A pharmacokinetic study found no sustained increases in blood or plasma ATP even with prolonged dosing up to 5 g/day, though high doses increased plasma uric acid.
Last reviewed: 2026-10-14 · 3 indexed studies
Set your location for accurate regulatory status
Saved on this device — no sign-in needed.
Overview
Oral ATP (branded as Peak ATP) is an enteric‑coated form of adenosine 5'-triphosphate marketed as an ergogenic supplement. Human trials report mixed effects on resistance exercise performance and small, inconsistent effects on muscular strength; oral ATP does not produce sustained increases in blood or plasma ATP in trials provided.
Mechanism & Function
Mechanism of Action
Extracellular ATP acts on purinergic receptors which modulate inflammation, muscle contractility and blood flow; however, oral ATP appears largely metabolised and does not reliably raise circulating ATP in the trials provided. Any ergogenic effects may relate to local intestinal or vascular purinergic signalling or metabolites rather than increased plasma ATP.
Physiological Role
ATP is the primary cellular energy currency and an endogenous ligand for purinergic receptors involved in neuromuscular function and vascular regulation.
Primary Pathways
Performance / Health Relevance
Trials tested resistance exercise performance and muscular strength. Evidence is mixed: one small acute study reported improved total work with 400 mg, while other trials found no clear plasma ATP changes and only modest, inconsistent strength gains with 150–225 mg/day.
Evidence Review
No meta-analyses or systematic reviews indexed for this ingredient yet.
Dimensions marked N/A have no indexed evidence of that class. They are shown as unavailable rather than scored.
Practical Use & Dosage
- Minimum Effective Dose
- 150 mg/day (some small trials)
- Optimal Range
- 150–400 mg/day; acute single 400 mg dose shown to improve resistance exercise in one small trial
- Upper / Caution Level
- 5000 mg/day associated with increased plasma uric acid in a 28‑day study; safety at very high doses not established
- Timing
- Acute benefit observed when 400 mg taken ~30 minutes before resistance exercise; chronic protocols used daily dosing for 14–28 days in trials
- Best Format
- Enteric‑coated oral capsules/pellets (used in trials)
- Bioavailability
- A pharmacokinetic trial reported no increase in blood or plasma ATP after prolonged oral dosing, suggesting oral ATP is largely metabolised before raising circulating ATP.
- Absorption Considerations
- Enteric coating was used in trials to improve intestinal delivery; despite this, plasma ATP did not rise in the provided pharmacokinetic study.
Safety & Interactions
Side Effects
- •Increase in plasma uric acid reported at very high doses (5 g/day)
Contraindications
- History of gout or hyperuricaemia (caution)
Who Should Avoid
- •People with gout or hyperuricaemia
- •Those with significant renal impairment (caution)
Monitoring
Consider monitoring serum uric acid if using high doses or in individuals with history of gout; liver and kidney parameters were normal in a 28‑day pharmacokinetic study at doses up to 5 g/day.
Frequently Asked Questions
Auto-generated from indexed evidence — dosage, safety, interactions, and more.
When is Peak ATP (Adenosine 5'-Triphosphate) typically used or indicated?
Peak ATP (Adenosine 5'-Triphosphate) is most commonly used for: Acute resistance exercise performance, Strength/power support, Ergogenic aid pre-workout. ATP is the primary cellular energy currency and an endogenous ligand for purinergic receptors involved in neuromuscular function and vascular regulation.
How does Peak ATP (Adenosine 5'-Triphosphate) work?
Extracellular ATP acts on purinergic receptors which modulate inflammation, muscle contractility and blood flow; however, oral ATP appears largely metabolised and does not reliably raise circulating ATP in the trials provided. Any ergogenic effects may relate to local intestinal or vascular purinergic signalling or metabolites rather than increased plasma ATP.
What is the recommended dose of Peak ATP (Adenosine 5'-Triphosphate)?
The optimal range is 150–400 mg/day; acute single 400 mg dose shown to improve resistance exercise in one small trial. with a minimum effective dose of 150 mg/day (some small trials). Best taken: Acute benefit observed when 400 mg taken ~30 minutes before resistance exercise; chronic protocols used daily dosing for 14–28 days in trials. Upper / caution level: 5000 mg/day associated with increased plasma uric acid in a 28‑day study; safety at very high doses not established.
What are the side effects of Peak ATP (Adenosine 5'-Triphosphate)?
Reported side effects include: Increase in plasma uric acid reported at very high doses (5 g/day). Monitoring: Consider monitoring serum uric acid if using high doses or in individuals with history of gout; liver and kidney parameters were normal in a 28‑day pharmacokinetic study at doses up to 5 g/day.
Who should avoid Peak ATP (Adenosine 5'-Triphosphate)?
Peak ATP (Adenosine 5'-Triphosphate) is generally not recommended for: People with gout or hyperuricaemia; Those with significant renal impairment (caution); and History of gout or hyperuricaemia (caution).
How strong is the evidence for Peak ATP (Adenosine 5'-Triphosphate)?
Evidence level: Limited (overall score 46/100), based on 3 indexed studies on SuppIndex.
Research & References (3)
Oral bioavailability of ATP after prolonged administration.
Randomised pharmacokinetic trial in 32 healthy adults given 0, 250, 1250 or 5000 mg/day enteric‑coated ATP for 28 days. Also administered 5000 mg on days 0 and 28 to assess acute response.
Effects of oral ATP supplementation on anaerobic power and muscular strength.
Double‑blind RCT in 27 healthy males comparing enteric‑coated ATP 150 mg, 225 mg or placebo over 14 days with measures of Wingate anaerobic power and muscular strength (1RM and repetitions to fatigue).
A Single Dose of Oral ATP Supplementation Improves Performance and Physiological Response During Lower Body Resistance Exercise in Recreational Resistance-Trained Males.
Randomised double‑blind crossover trial in 11 recreational resistance‑trained men testing a single 400 mg oral ATP dose vs placebo; subjects performed 4 sets of half‑squats to failure at 80% 1RM.
Related Ingredients
Other top-rated ingredients in Ergogenic Compounds.
Creatine Monohydrate
94/100A naturally occurring nitrogenous organic acid that facilitates recycling of adenosine triphosphate (ATP) in muscle and brain tissue via the phosphocreatine shuttle.
Maltodextrin
78/100Short-chain α-1,4 linked glucose polymer that is rapidly hydrolysed by brush-border maltase to glucose; near-equivalent glycaemic response to glucose but lower osmolality at concentration.
Cyclic Dextrin (HBCD)
72/100Produced via cyclic-glucanotransferase action on amylopectin, HBCD forms cluster-like macromolecules ~160 kDa that solubilise at low osmolality (≈4 mOsm/L) and clear the stomach faster than maltodextrin or glucose polymers.
Research Overview
Limited EvidenceCite this ingredient
One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.
Stable URL
https://thesuppindex.com/ingredients/peak-atp-adenosine-5-triphosphate
SuppIndex. (2026). Peak ATP (Adenosine 5'-Triphosphate): Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/peak-atp-adenosine-5-triphosphate
Based on 3 indexed studies · Evidence level: Limited.
Goal Ratings
Stack Compatibility
No interactions reported in the provided abstracts; evidence is limited.